- Video Center
- Social Media
- Media Contacts
Leverkusen, Germany / St. Louis, September 28, 2020 – Bayer announced today that the European Commission has authorized XtendFlex soybean technology for food, feed, import and processing in the European Union. This milestone represents the final key authorization for XtendFlex soybeans. With this approval in hand, Bayer can now look forward to a full launch in the United States and Canada in 2021 and expects to be in a strong position to supply 20 million U.S. soy acres when the selling season arrives.
“XtendFlex soybeans will be Bayer’s second major product launch in soybeans in the last 5 years,” said Lisa Safarian, President of Crop Science North America. “The upcoming launch in 2021 highlights the strength of the Bayer soybean pipeline, as well as the investment that Bayer continues to make in our soybean portfolio and the Roundup Ready Xtend Crop System. XtendFlex soybeans are the latest example of Bayer developing innovative products to help farmers meet challenges on their farm.”
XtendFlex soybeans, Bayer’s newest soybean technology, are built upon the high-yielding Roundup Ready 2 Xtend soybean technology that growers have grown to trust with the additional tolerance to glufosinate herbicides. XtendFlex soybeans provide growers with additional flexibility to manage tough-to-control and resistant weeds.
“We’ve seen great demand for XtendFlex soybeans from our customers,” said Lisa Streck, Bayer soybean launch lead. “Based on that demand, we’ve developed a supply plan to meet the market demand in 2021, across all maturities, Bayer brands and licensees. We expect the launch of XtendFlex to match the launch scale of Roundup Ready 2 Xtend soybeans, which were planted on 20 million acres in their first year of commercial availability. This technology offers outstanding yield potential and weed control flexibility that will benefit soybean farmers across the U.S.”
To learn more about XtendFlex soybeans, please visit RoundupReadyXtend.com.
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2019, the Group employed around 104,000 people and had sales of 43.5 billion euros. Capital expenditures amounted to 2.9 billion euros, R&D expenses to 5.3 billion euros. For more information, go to www.bayer.com.
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
View Download Center